Physician profile
Mark Randall Sexton
NPI 1982678702
$17,766.81
in general payments reported to CMS, 2019-2025
62 companies · $1,839 in 2025
The $1,839 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,403 · 2020: $2,086 · 2021: $2,811 · 2022: $2,670 · 2023: $3,097 · 2024: $2,862 · 2025: $1,839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,782 · Education: $15.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,781.92 |
| Education | $15.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,198.85 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,780.70 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,495.68 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,438.96 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $960.54 | 2021-2025 | |
| Glaxosmithkline, LLC. | $834.03 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $830.30 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $696.56 | 2019-2025 | Jardiance |
| Antares Pharma, INC. | $538.70 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Astellas Pharma US INC | $426.18 | 2019-2025 | Veozah |
| Abbott Laboratories | $412.22 | 2021-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $391.24 | 2019-2024 | Spravato |
| Amgen INC. | $380.47 | 2019-2025 | Repatha, Otezla, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $363.17 | 2019-2025 | Trintellix |
| Corium, LLC | $361.53 | 2022-2024 | Azstarys |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sexton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.